Safety and Tolerability of Lanreotide Autogel/Depot (LAN) in Patients (pts) with Neuroendocrine Tumours (NETs): Pooled Analysis of Clinical Studies

被引：0
|
作者：
Phan, A. T. [1 ]
Wolin, E. M. [2 ]
Fisher, G. A. [3 ]
Ruszniewski, P. [4 ]
Pavel, M. [5 ]
Liyanage, N. [6 ]
Mirakhur, B. [7 ]
Braun, S. [6 ]
Caplin, M. [8 ]
Vinik, A., I [9 ]
机构：
[1] Univ New Mexico, Ctr Canc, Albuquerque, NM 87131 USA
[2] Montefiore Einstein Ctr Canc Care, Bronx, NY USA
[3] Stanford Univ, Stanford, CA 94305 USA
[4] Beaujon Hosp, Clichy, France
[5] Charite Univ Med Berlin, Berlin, Germany
[6] Ipsen, Les Ulis, France
[7] Ipsen, Basking Ridge, NJ USA
[8] Royal Free Hosp, London, England
[9] Eastern Virginia Med Sch, Norfolk, VA 23501 USA
来源：
NEUROENDOCRINOLOGY | 2017年 / 105卷
关键词：
lanreotide; safety;
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
K17
引用
收藏
页码：206 / 206
页数：1
相关论文
共 50 条
  • [41] Lanreotide Autogel/Depot (LAN) Post-Octreotide Long-Acting Release (OCT) for Safe and Tolerable Treatment of Gastroenteropancreatic Neuroendocrine Tumors (GEP-NETs)
    不详
    CLINICAL ADVANCES IN HEMATOLOGY & ONCOLOGY, 2016, 14 (12) : 12 - 13
  • [42] Lanreotide Autogel/Depot (LAN) Post-Octreotide Long-Acting Release (OCT) for Safe and Tolerable Treatment of Gastroenteropancreatic Neuroendocrine Tumors (GEP-NETs)
    Saif, M. Wasif
    Fu, Julie
    Smith, Melissa
    Maloney, Antonia
    Relias, Valerie
    JWeinstein, Barbara
    Suarez, Yvelisse N.
    Goodman, Martin D.
    Daly, Kevin P.
    PANCREAS, 2017, 46 (03) : 436 - 436
  • [43] Effect of lanreotide autogel/depot (LAN) on tumor growth rate (TGR) in patients with metastatic bronchopulmonary neuroendocrine tumors (BP-NETs): Exploratory data from the phase 3 SPINET study
    Baudin, E.
    Hoersch, D.
    Singh, S.
    Caplin, M.
    Ferone, D.
    Wolin, E.
    Capdevila, J.
    Buikhuisen, W.
    Raderer, M.
    Houchard, A.
    Thanh, Truong X. M.
    Reidy-Lagunes, D.
    JOURNAL OF NEUROENDOCRINOLOGY, 2022, 34 : 165 - 165
  • [44] Quality of Life (QoL) with Lanreotide Autogel/Depot (LAN) vs. Placebo in Patients with Enteropancreatic Neuroendocrine Tumors: Results From the CLARINET Core Study
    Ruszniewski, Philippe
    Phan, Alexandria T.
    Caplin, Martyn E.
    Pavel, Marianne E.
    Cwikla, Jaroslaw B.
    Raderer, Markus
    Sedlackova, Eva
    Cadiot, Guillaume
    Wall, Lucy
    Rindi, Guido
    Langley, Alison
    Gomez-Panzani, Edda
    PANCREAS, 2015, 44 (02) : 357 - 357
  • [45] Exploratory Assessment of the Clinical Value of Baseline (BL) Circulating Tumour Cells (CTC) to Predict Symptomatic Response in Pts with Functioning Midgut Neuroendocrine Tumours (NETs) Receiving Lanreotide Autogel (LAN): CALM-NET Study Results.
    Meyer, T.
    Khan, M.
    Toumpanakis, C.
    Shetty, S.
    Houchard, A.
    Goyal, A.
    Shah, T.
    NEUROENDOCRINOLOGY, 2019, 108 : 131 - 131
  • [46] An Exploratory Patient Centric Analysis of the ELECT Trial: A Phase 3 Study of Efficacy and Safety of Lanreotide Autogel/Depot (LAN) Treatment for Patients With Carcinoid Syndrome (CS)
    Duchateau, Luc
    Lescrauwaet, Benedicte
    Blot, Koenraad
    Liyanage, Nilani
    Ray, David
    Lowenthal, Susan Pitman
    Braun, Stephan
    Mirakhur, Beloo
    PANCREAS, 2018, 47 (03) : 338 - 338
  • [47] Efficacy of lanreotide autogel/depot (LAN) vs placebo (PBO) for symptomatic control of carcinoid syndrome (CS) in neuroendocrine tumor (NET) patients from the ELECT
    Wolin, E. M.
    Fisher, G. A.
    Kunz, P. L.
    Liyanage, N.
    Lowenthal, S. P.
    Mirakhur, B.
    Pommier, R. F.
    Shaheen, M.
    Vinik, A.
    ANNALS OF ONCOLOGY, 2016, 27
  • [48] Tumour growth rate (TGR) when using lanreotide Autogel® (LAN) before, during and after peptide receptor radionuclide therapy (PRRT) in advanced neuroendocrine tumours (NETs)
    Prasad, V.
    Srirajaskanthan, R.
    Grana, C. M.
    Baldari, S.
    Shah, T.
    Lamarca, A.
    Courbon, F.
    Scheidhauer, K.
    Baudin, E.
    Truong-Thanh, X-M.
    Houchard, A.
    Bodei, L.
    ANNALS OF ONCOLOGY, 2018, 29
  • [49] Multivariate analysis of progression-free survival in the CLARINET study of lanreotide Autogel/Depot vs placebo identifies prognostic factors in neuroendocrine tumours
    Wolin, E.
    Caplin, M.
    Pavel, M.
    Cwikla, J.
    Phan, A.
    Raderer, M.
    Sedlackova, E.
    Cadiot, G.
    Capdevila, J.
    Wall, L.
    Rindi, G.
    Langley, A.
    Gomez-Panzani, E.
    Ruszniewski, P.
    EUROPEAN JOURNAL OF CANCER, 2015, 51 : S461 - S461
  • [50] OPERA: Observational study of perception of information and quality of life (QoL) in patients with gastroenteropancreatic neuroendocrine tumors (GEP-NETs) starting Lanreotide Autogel (LAN)
    Hautefeuille, V
    Walter, T.
    Do Cao, C.
    Coriat, R.
    Dominguez, S.
    Mineur, L.
    Gueguen, D.
    Houchard, A.
    Mouawad, C.
    Anota, A.
    Hammel, P.
    JOURNAL OF NEUROENDOCRINOLOGY, 2021, 33 : 136 - 136
12345